Download PDF
Drug Res (Stuttg) 2013; 63(08): 435-438
DOI: 10.1055/s-0033-1345149
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

A Simply HPLC Method for Determination of Cefpodoxime in Chinese Volunteer and Pharmacokinetic Study

J-h. Zhang
1   Department of Pediatrics of Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
,
S. Guo
1   Department of Pediatrics of Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
,
M. Xu
1   Department of Pediatrics of Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
,
L-X. Wu
1   Department of Pediatrics of Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
› Author Affiliations
Further Information

Publication History

received 19 March 2013

accepted 17 April 2013

Publication Date:
15 May 2013 (online)

Also available at
    Permissions and Reprints

Abstract

A sensitive HPLC method was developed for the determination of cefpodoxime in human plasma. After protein precipitation with acetonitrile, sample was injected into the HPLC system for analysis. The chromatographic separation was carried out on a Diamonsil C18 column with a mobile phase consisting of acetonitrile-water. The mobile phase composed of water (containing 20 mmol/L monoammonium phosphate) and acetonitrile (90: 10, v/v). The detection wavelength was set at 254 nm. The standard curve for cefpodoxime was linear over the concentration range of 0.05–8 μg/mL with a lower limit of quantification of 0.05 μg/mL. The intra- and inter-day RSD values were lower than 10%, and the RE values were within±5%. For the pharmacokinetic analysis of plasma, the mean (SD) values obtained for the formulation were: Cmax, 4.21 (0.62) µg/mL; Tmax, 2.47 (0.61) h; t1/2, 2.38 (0.46) h; AUC0-24 h, 21.13 (3.39) µg/mL/h; and AUC0-∞, 23.34 (3.87) µg/mL/h; MRT, 2.21 (0.41) h, respectively.

Key words

cefpodoxime - HPLC - pharmacokinetics
 

  • References

  • 1 Komai T, Kawai K, Tsubaki H et al. Absorption, distribution, metabolism and excretion of CS-807, a new oral cephemantibiotic, in experimental animals. Chemotherapy (Tokyo) 1988; 36: 229-240
    PubMedGoogle Scholar
  • 2 Tremblay D, Dupront A, Ho C et al. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother 1990; 26: 21-28
    PubMedGoogle Scholar
  • 3 Aggarwal A, Rath S. Cefpodoxime – utility in respiratory tract infections and typhoid fever. Indian J Pediatr 2004; 71: 413-415
    CrossrefPubMedGoogle Scholar
  • 4 Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs 2001; 3: 137-158
    PubMedGoogle Scholar
  • 5 Camus F, Deslandes A, Harcouet L et al. High-performance liquid chromatographic method for the determination of cefpodoxime levels in plasma and sinus mucosa. J Chromatogr B 1994; 656: 383-388
    PubMedGoogle Scholar
  • 6 Kumar V, Madabushi R, Lucchesi MB et al. Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. J Vet Pharmacol Ther 2011; 34: 130-135
    CrossrefPubMedGoogle Scholar
  • 7 U.S. Department of Health and Human Services . Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM), Guidance for Industry-Bioanalytical Method Validation, Center for Drug Evaluation and Research (CDER), Rockville, Md, USA 2001;
    PubMed